Your browser doesn't support javascript.
loading
Persistence and adherence to biologic therapies in juvenile idiopathic arthritis.
Nieto-González, Juan Carlos; Trives-Folguera, Laura; Melgarejo-Ortuño, Alejandra; Ais, Aranzazu; Serrano-Benavente, Belén; Sanjurjo, María; Álvaro-Gracia, José María; Sáez, Indalecio Monteagudo.
Afiliación
  • Nieto-González JC; Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. juancarlos.nietog@gmail.com.
  • Trives-Folguera L; Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Melgarejo-Ortuño A; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Ais A; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Serrano-Benavente B; Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Sanjurjo M; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Álvaro-Gracia JM; Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Sáez IM; Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Sci Rep ; 11(1): 16195, 2021 08 10.
Article en En | MEDLINE | ID: mdl-34376702
Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that often requires biological therapy to control its activity. Medication persistence and adherence are important aspects on which we have scarce information. We performed a longitudinal, retrospective, and observational study based on data from the daily clinical management of JIA patients. We recorded clinical remission at 6 and 12 months. Persistence of biological therapy was evaluated using Kaplan-Meier curves, and adherence was assessed using the medication possession ratio (MPR). We included 68 patients who received biological therapy. Of these, 11 (16.2%) and 5 (7.4%) required a second and third drug, respectively. The persistence rate for biological therapy at 5 years was 64%, with no differences between the first and second lines. Adherence was high during the first year of treatment (MPR80: 96.3%) and also in the second and third years (MPR80: 85.2% and 91.8%, respectively). Persistence and adherence to biological therapy were remarkably high in our JIA cohort. Adherence to biological treatments could be related to a higher probability of fulfilling the Wallace remission criteria at 6 months, although this was not confirmed at 12 months.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Juvenil / Productos Biológicos / Terapia Biológica / Índice de Severidad de la Enfermedad / Sistema de Registros / Antirreumáticos / Cumplimiento de la Medicación Tipo de estudio: Observational_studies / Prognostic_studies Límite: Child / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Juvenil / Productos Biológicos / Terapia Biológica / Índice de Severidad de la Enfermedad / Sistema de Registros / Antirreumáticos / Cumplimiento de la Medicación Tipo de estudio: Observational_studies / Prognostic_studies Límite: Child / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido